GH1 and obesity due to melanocortin 4 receptor deficiency: Thus, pharmacological compounds that are capable of targeting GH signaling may prevent compensatory decreases in energy expenditure during F.R. and consequently represent a promising approach to facilitate weight loss and improve the efficacy of obesity treatments.